Valneva Shows Promising Immune Response with IXCHIQ® for Adolescents
Valneva SE (NASDAQ: VALN; Euronext Paris: VLA), a pioneering vaccine company, recently shared encouraging data from its Phase 3 trial for IXCHIQ®, a single-dose chikungunya vaccine. One year after vaccination, the vaccine demonstrated a remarkable 98.3% sero-response rate among adolescents aged 12 to 17. This durability of response highlights the vaccine's efficacy and paves the way for potential label expansion in multiple regions.
One-Year Immunity Data Supports Regulatory Applications
The VLA1553-321 trial revealed that the one-year sero-response rate was achieved in a population of participants who were negative for chikungunya virus (CHIKV) at baseline. Following vaccination, 232 out of 236 participants maintained immunity after one year, reinforcing the findings of earlier assessments conducted at six months and 28 days post-vaccination. These results affirm the long-lasting antibody response instigated by a single administration of the vaccine.
Safety Profile of IXCHIQ® in Adolescents
In addition to its efficacy, data from the one-year study confirmed that IXCHIQ® was generally well tolerated among adolescents. An Independent Data Safety Monitoring Board (IDSMB) conducted consistent safety assessments throughout the trial without reporting any significant safety issues.
Expert Insight on the Vaccine's Importance
Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, emphasized the importance of this vaccine, noting, "These additional adolescent data confirm IXCHIQ®'s ability to induce a robust, long-lasting antibody response in both younger people and adults with a single vaccination. Given the substantial risk that chikungunya presents to individuals residing in or traveling to endemic regions, it's imperative to ensure the vaccine is available to all age groups and offers long-term protection." Valneva is keen to ensure that their vaccine becomes widely accessible, particularly in low- and middle-income countries where healthcare resources are limited.
Collaboration to Enhance Vaccine Access
The VLA1553-321 trial was conducted in collaboration with Instituto Butantan in Brazil, backed by the Coalition for Epidemic Preparedness Innovations (CEPI) and the EU’s Horizon 2020 program. This trial was significant as it engaged individuals who had previously contracted CHIKV, making it the first of its kind in an endemic area.
Next Steps for Regulatory Approval
Data from this trial has propelled Valneva to submit applications for label extensions with regulatory entities in the U.S., Europe, and Canada to include adolescents aged 12 to 17 years. Furthermore, it may facilitate the licensure of IXCHIQ® in Brazil and several countries across Latin America.
Valneva's Ongoing Commitment to Global Health
In an exciting development, Valneva recently expanded its partnership with CEPI through a substantial $41.3 million grant aimed at increasing the availability of IXCHIQ® in low- and middle-income countries. This funding will help facilitate post-market studies, broaden access to the vaccine, and support label extensions for various vulnerable populations, including children, adolescents, and pregnant women.
Exclusive Licensing Agreement to Spearhead Distribution
Valneva recently secured an exclusive licensing agreement with the Serum Institute of India (SII), which is notable for being the largest vaccine manufacturer globally by volume. This strategic agreement aims to ensure priority supply of IXCHIQ® at an affordable price to public health markets in countries affected by outbreaks.
Chikungunya Vaccine: Addressing an Unmet Need
IXCHIQ® is hailed as the world’s first and only licensed chikungunya vaccine. It is currently approved for individuals aged 18 and older in the U.S., Europe, and Canada. Following its anticipated approval in Brazil, Valneva is also looking forward to receiving marketing authorization in the United Kingdom soon.
Understanding Chikungunya Virus and Its Impact
CHIKV is a mosquito-borne virus known to cause severe fever, joint pain, and other debilitating symptoms, which can linger for years. First identified in 2004, it has sparked outbreaks worldwide, particularly in more than 110 countries across diverse continents. Health authorities, such as the World Health Organization (WHO), regard chikungunya as an escalating public health concern, especially as climate change continues to expand the geographical limits of its transmission.
About Valneva SE
Valneva SE is committed to developing, manufacturing, and commercializing vaccines targeting infectious diseases with significant unmet medical needs. Their approach is centered on leveraging their expertise across different vaccine modalities, striving to provide innovative solutions including the only chikungunya vaccine available today. Additionally, their pipeline includes promising candidates for Lyme disease, Zika virus, and other pressing global health challenges.
Frequently Asked Questions
What is IXCHIQ®?
IXCHIQ® is the world's first licensed chikungunya vaccine developed by Valneva SE, intended for preventing disease caused by the chikungunya virus.
What age group is IXCHIQ® approved for?
Currently, IXCHIQ® is approved for individuals aged 18 years and older, with applications pending for adolescents aged 12 to 17.
What were the key findings of the Phase 3 trial?
The Phase 3 trial revealed a sustained immune response of 98.3% one year after a single vaccination in adolescents, along with a favorable safety profile.
How does Valneva ensure vaccine accessibility in low-income regions?
Valneva's collaboration with CEPI and the Serum Institute of India aims to enhance vaccine access in low- and middle-income countries, focusing on affordability.
Why is chikungunya considered a public health concern?
Chikungunya virus poses significant health risks, causing debilitating symptoms and widespread outbreaks across the globe, necessitating effective vaccination strategies.
